A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma

Inclusion Criteria: 1. Subjects fully understand and voluntarily participate in this study and sign informed consent; 2. Age ≥18, without gender limitation; 3. Histologically confirmed diagnosis of unresectable locally advanced or metastatic gastric carcinoma, including gastroesophageal junction carcinoma; 4. Suitable to receive the study drug as decided by the investigator; 5. At least one measurable lesion according to RECIST v1.1; 6. ECOG performance status of 0 to 2; 7. Life expectancy ≥ 12 weeks; 8. AEs from the previous treatment have resolved to ≤ Grade 1 based on CTCAE (except for the toxicity without safety risk judged by the investigator, such as hair loss, hyperpigmentation); 9. Adequate organ function; 10. Subjects of childbearing potential must agree to use effective contraceptive measures. Female subjects must have a negative pregnancy test before enrolment; 11. Fully comply with the protocol. Exclusion Criteria: 1. History of allergy to mitoxantrone hydrochloride or any excipients of the study drug; 2. Untreated or symptomatic central nervous system (CNS) metastases; 3. Amenable to curative surgery ( radical excision); 4. Pleural effusion, pericardial effusion or peritoneal effusion with overt clinical symptoms (except for those have a drainage within 1 month before screening, asymptomatic and the effusion only detectable by imageological examination); 5. Intestinal obstruction with overt clinical symptom and requiring treatment; 6. CTCAE Grade 3 or Grade 4 gastrointestinal hemorrhage within 12 weeks prior to the first dose administration; 7. History of allotransplantation; 8. Known hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or other active viral infection; 9. Serious infection or interstitial pneumonia within 1 week prior to the first dose administration; 10. Use of other anticancer treatment within 4 weeks prior to the first dose administration; 11. Enrolled in any other clinical trails and had recieved treatment within 4 weeks prior to the first dose administration; 12. Major surgery within 3 months prior to the first dose administration, or have a surgical schedule during the study period; 13. Thrombosis or thromboembolism within 6 months prior to screening; 14. History of, or known additional malignant tumor within 3 years, except for tumors have been cured and have not recurred, and carcinoma in situ; 15. Impaired cardiac function or serious cardiac disease; 16. Previous treatment with adriamycin or other anthracyclines, and the total cumulative dose of prior adriamycin or equivalent is \>350 mg/m2. 17. Pregnant or lactating female; 18. Serious and/or uncontrolled systemic diseases;